cysteine and serine rich nuclear protein 3Genealiases: FAM130A2 · MBU1 · PPP1R73 · TAIP-2 · TAIP2
Q-omics provides the consensus-scored CSRNP3 profile across patient tissues and cancer cell-line models. CSRNP3 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CSRNP3 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, CSRNP3 RNA expression shows 20,437 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, and GBM as cancer lineages where CSRNP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSRNP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSRNP3 survival associations across molecular data types. CSRNP3 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSRNP3 RNA expression–survival associations across cancer types. High CSRNP3 expression shows unfavorable associations in BLCA and CESC, but favorable associations in KIRC, LGG, KIRP and LUSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CSRNP3 RNA expression.
This table summarizes CSRNP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CSRNP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSRNP3 shows lower tumor expression in KIRC, KICH, BLCA, BRCA, COAD and READ. The KIRC box plot shows higher CSRNP3 RNA expression in normal versus tumor tissue (log2 FC = −1.136, t-test p < 0.001).
This table shows molecular features associated with CSRNP3 in patient tissues and cancer cell lines. In patient samples, CSRNP3 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, CSRNP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OESOPHAGUS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
